Compare Logitech International SA (LOGI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Pfizer Inc — how do they compare? Logitech International SA trades at $101.7 (market cap $14.65B), while Pfizer Inc trades at $24.92 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 9.6× Logitech International SA's market cap, and Pfizer Inc pays the higher dividend (6.95%). Which is the better fit depends on your goals.
| LOGI | PFE | |
|---|---|---|
Market Cap | $14.65B | $141.06B |
Sector | Technology | Health |
52-Week High | $126.69 | $28.56 |
52-Week Low | $85.84 | $23.29 |
Enterprise Value | $13.00B | $191.72B |
Dividend Yield | 1.67% | 6.95% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $102.91, up 0.08% on the day, with a bullish technical signal from moving averages and support at $101. The company shows strong profitability with a 43.2% gross margin and 32.78% ROE, while recent earnings beats and a $1.36 dividend highlight financial health. Revenue is projected to grow to $4.8B in 2026, with net income reaching $711M.
Outlook remains positive with a consensus price target of $113, offering ~10% upside, driven by B2B and AI product growth. Risks include competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid solid fundamentals.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
